NATERA INC (NTRA) Stock Fundamental Analysis

NASDAQ:NTRA • US6323071042

212.12 USD
-4.24 (-1.96%)
At close: Feb 20, 2026
212.12 USD
0 (0%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, NTRA scores 4 out of 10 in our fundamental rating. NTRA was compared to 521 industry peers in the Biotechnology industry. While NTRA has a great health rating, there are worries on its profitability. NTRA is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • NTRA had negative earnings in the past year.
  • NTRA had a positive operating cash flow in the past year.
  • NTRA had negative earnings in each of the past 5 years.
  • NTRA had negative operating cash flow in 4 of the past 5 years.
NTRA Yearly Net Income VS EBIT VS OCF VS FCFNTRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

  • NTRA has a better Return On Assets (-16.97%) than 78.12% of its industry peers.
  • NTRA's Return On Equity of -24.69% is fine compared to the rest of the industry. NTRA outperforms 79.85% of its industry peers.
Industry RankSector Rank
ROA -16.97%
ROE -24.69%
ROIC N/A
ROA(3y)-26.97%
ROA(5y)-28.74%
ROE(3y)-50.12%
ROE(5y)-53.96%
ROIC(3y)N/A
ROIC(5y)N/A
NTRA Yearly ROA, ROE, ROICNTRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

  • NTRA has a Gross Margin of 63.66%. This is in the better half of the industry: NTRA outperforms 79.65% of its industry peers.
  • NTRA's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NTRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.09%
GM growth 5Y7.51%
NTRA Yearly Profit, Operating, Gross MarginsNTRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NTRA has been increased compared to 1 year ago.
  • Compared to 5 years ago, NTRA has more shares outstanding
  • The debt/assets ratio for NTRA has been reduced compared to a year ago.
NTRA Yearly Shares OutstandingNTRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NTRA Yearly Total Debt VS Total AssetsNTRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 30.74 indicates that NTRA is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 30.74, NTRA belongs to the top of the industry, outperforming 92.71% of the companies in the same industry.
  • NTRA has a debt to FCF ratio of 0.86. This is a very positive value and a sign of high solvency as it would only need 0.86 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.86, NTRA belongs to the top of the industry, outperforming 93.86% of the companies in the same industry.
  • A Debt/Equity ratio of 0.06 indicates that NTRA is not too dependend on debt financing.
  • The Debt to Equity ratio of NTRA (0.06) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.86
Altman-Z 30.74
ROIC/WACCN/A
WACC8.68%
NTRA Yearly LT Debt VS Equity VS FCFNTRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 3.27 indicates that NTRA has no problem at all paying its short term obligations.
  • NTRA has a Current ratio of 3.27. This is in the lower half of the industry: NTRA underperforms 61.61% of its industry peers.
  • NTRA has a Quick Ratio of 3.13. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of NTRA (3.13) is worse than 60.27% of its industry peers.
Industry RankSector Rank
Current Ratio 3.27
Quick Ratio 3.13
NTRA Yearly Current Assets VS Current LiabilitesNTRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The earnings per share for NTRA have decreased strongly by -30.11% in the last year.
  • NTRA shows a strong growth in Revenue. In the last year, the Revenue has grown by 38.17%.
  • The Revenue has been growing by 41.20% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-30.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.15%
Revenue 1Y (TTM)38.17%
Revenue growth 3Y39.47%
Revenue growth 5Y41.2%
Sales Q2Q%34.66%

3.2 Future

  • The Earnings Per Share is expected to grow by 32.46% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 20.38% on average over the next years. This is a very strong growth
EPS Next Y-60.35%
EPS Next 2Y-12.12%
EPS Next 3Y22.56%
EPS Next 5Y32.46%
Revenue Next Year34.5%
Revenue Next 2Y25.29%
Revenue Next 3Y22.99%
Revenue Next 5Y20.38%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NTRA Yearly Revenue VS EstimatesNTRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
NTRA Yearly EPS VS EstimatesNTRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NTRA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NTRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTRA Price Earnings VS Forward Price EarningsNTRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

  • NTRA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NTRA is cheaper than 90.21% of the companies in the same industry.
Industry RankSector Rank
P/FCF 315.44
EV/EBITDA N/A
NTRA Per share dataNTRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NTRA's earnings are expected to grow with 22.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.12%
EPS Next 3Y22.56%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NTRA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NATERA INC

NASDAQ:NTRA (2/20/2026, 8:00:01 PM)

After market: 212.12 0 (0%)

212.12

-4.24 (-1.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-04
Inst Owners92.29%
Inst Owner Change-0.3%
Ins Owners2.98%
Ins Owner Change-1.31%
Market Cap29.51B
Revenue(TTM)2.12B
Net Income(TTM)-309.19M
Analysts84.44
Price Target261 (23.04%)
Short Float %2.53%
Short Ratio2.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-42.99%
Min EPS beat(2)-68.19%
Max EPS beat(2)-17.78%
EPS beat(4)1
Avg EPS beat(4)-16.42%
Min EPS beat(4)-68.19%
Max EPS beat(4)23.06%
EPS beat(8)5
Avg EPS beat(8)10.4%
EPS beat(12)8
Avg EPS beat(12)8.32%
EPS beat(16)11
Avg EPS beat(16)6.86%
Revenue beat(2)2
Avg Revenue beat(2)12.87%
Min Revenue beat(2)12.51%
Max Revenue beat(2)13.23%
Revenue beat(4)4
Avg Revenue beat(4)11.23%
Min Revenue beat(4)8.92%
Max Revenue beat(4)13.23%
Revenue beat(8)8
Avg Revenue beat(8)12.89%
Revenue beat(12)11
Avg Revenue beat(12)9.45%
Revenue beat(16)14
Avg Revenue beat(16)7.54%
PT rev (1m)6.71%
PT rev (3m)31.35%
EPS NQ rev (1m)-1.96%
EPS NQ rev (3m)-34.09%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)-20.77%
Revenue NQ rev (1m)2.91%
Revenue NQ rev (3m)7.98%
Revenue NY rev (1m)0.4%
Revenue NY rev (3m)6.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.94
P/FCF 315.44
P/OCF 151.9
P/B 23.57
P/tB 23.57
EV/EBITDA N/A
EPS(TTM)-2.29
EYN/A
EPS(NY)-1.92
Fwd EYN/A
FCF(TTM)0.67
FCFY0.32%
OCF(TTM)1.4
OCFY0.66%
SpS15.21
BVpS9
TBVpS9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.97%
ROE -24.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.66%
FCFM 4.42%
ROA(3y)-26.97%
ROA(5y)-28.74%
ROE(3y)-50.12%
ROE(5y)-53.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.09%
GM growth 5Y7.51%
F-Score5
Asset Turnover1.16
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.86
Debt/EBITDA N/A
Cap/Depr 270.95%
Cap/Sales 4.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.27
Quick Ratio 3.13
Altman-Z 30.74
F-Score5
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)232.23%
Cap/Depr(5y)273.02%
Cap/Sales(3y)4.66%
Cap/Sales(5y)5.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.15%
EPS Next Y-60.35%
EPS Next 2Y-12.12%
EPS Next 3Y22.56%
EPS Next 5Y32.46%
Revenue 1Y (TTM)38.17%
Revenue growth 3Y39.47%
Revenue growth 5Y41.2%
Sales Q2Q%34.66%
Revenue Next Year34.5%
Revenue Next 2Y25.29%
Revenue Next 3Y22.99%
Revenue Next 5Y20.38%
EBIT growth 1Y-45.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-60%
EBIT Next 3Y28.21%
EBIT Next 5Y35.26%
FCF growth 1Y130.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y171.97%
OCF growth 3YN/A
OCF growth 5YN/A

NATERA INC / NTRA FAQ

What is the ChartMill fundamental rating of NATERA INC (NTRA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to NTRA.


What is the valuation status of NATERA INC (NTRA) stock?

ChartMill assigns a valuation rating of 2 / 10 to NATERA INC (NTRA). This can be considered as Overvalued.


How profitable is NATERA INC (NTRA) stock?

NATERA INC (NTRA) has a profitability rating of 2 / 10.


How financially healthy is NATERA INC?

The financial health rating of NATERA INC (NTRA) is 7 / 10.


What is the expected EPS growth for NATERA INC (NTRA) stock?

The Earnings per Share (EPS) of NATERA INC (NTRA) is expected to decline by -60.35% in the next year.